Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.71 |
| ▸ | KDR | P35968 | 8/20 | 0.71 |
| ▸ | RET | P07949 | 5/20 | 0.71 |
| ▸ | CLK1 | P49759 | 2/20 | 0.71 |
| ▸ | FBP1 | P09467 | 2/20 | 0.71 |
| ▸ | KIF5B | P33176 | 2/20 | 0.71 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.71 |
| ▸ | AURKA | O14965 | 1/20 | 0.71 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.71 |
| ▸ | INSR | P06213 | 1/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.71 |
| ▸ | FLT4 | P35916 | 1/20 | 0.71 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.71 |
| ▸ | TEK | Q02763 | 1/20 | 0.71 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.71 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.71 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.70 |
| ▸ | LCK | P06239 | 5/20 | 0.69 |
| ▸ | FLT1 | P17948 | 1/20 | 0.64 |
| ▸ | GAK | O14976 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792594 | 0.90 | EGFR (0.74) | EGFRKDRRETCLK1FBP1 | |
| SCHEMBL20812874 | 0.85 | EGFR (0.80) | EGFRKDRRETCLK1FBP1 | |
| SCHEMBL5864719 | 0.85 | KDR (0.82) | EGFRKDRRETCLK1FBP1 | |
| SCHEMBL3533221 | 0.84 | EGFR (0.80) | EGFRKDRRETCLK1KIF5B | |
| SCHEMBL6783334 | 0.84 | KDR (0.74) | EGFRKDRRETCLK1KIF5B | |
| Hydrochloric Acid SCHEMBL8871198 | 0.83 | EGFR (0.80) | EGFRKDRRETCLK1KIF5B | |
| SCHEMBL5478005 | 0.83 | EGFR (1.00) | EGFRKDRRETCLK1FBP1 | |
| SCHEMBL5565137 | 0.83 | EGFR (1.00) | EGFRKDRRETCLK1KIF5B | |
| SCHEMBL2099106 | 0.83 | EGFR (1.00) | EGFRKDRCLK1FBP1AURKA | |
| SCHEMBL6787016 | 0.83 | KDR (0.74) | EGFRKDRRETCLK1FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20110077233-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-7579473-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | EGFR 124/4885KDR 4/4885RET 8/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | EGFR 124/4885KDR 4/4885RET 8/4885 |
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | EGFR 166/4885KDR 5/4885RET 27/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | EGFR 124/4885KDR 4/4885RET 8/4885 |
| US-20110077233-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | EGFR 181/4885KDR 5/4885RET 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.